Partners Eisai and Biogen are moving their oral beta-secretase cleaving enzyme (BACE) inhibitor E2609 into Phase III. There they join other major biopharmas…
Editas Medicine has done a deal with gene therapy small cap Adverum to introduce genome editing into diseased retina via gene therapy vectors.
With Ablynx's rheumatoid arthritis drug missing its primary endpoint, it is as unclear as ever whether AbbVie will pay $75 million to license the program.
Pfizer has reconsidered its Lucentis biosimilar as competition mounts and ended a development deal with small cap Pfenex.
MEI Pharma has offloaded the global rights to its AML drug pracinostat to Helsinn in a $464 million deal.
The FDA has placed a partial clinical hold on the pivotal clinical trial of a T-cell candidate from Adaptimmune Therapeutics.
Roche and Inovio Pharmaceuticals had hoped to develop immunotherapies to treat prostate cancer and hepatitis B when they first partnered in 2013. But now that…
Sorrento Therapeutics is creating a joint venture with South Korea’s CHA Biotech to develop chimeric antigen receptor modified cellular therapies based on…
A scant 6 months after rounding up $51 million in a Series A round, Adicet Bio has secured a 5-year deal with Regeneron Pharmaceuticals.
Small cap Advaxis has a new preclinical immuno-oncology deal with industry giant Amgen that gives it $65 million in an upfront payment and investment.